4 Key Takeaways:
- Head-to-head trials show IL-17s like ixekizumab outperform traditional TNF inhibitors and even some IL-23s in early, fast action.
- Precision therapy based on site (scalp, nails, genitalia) and comorbidities is now guiding real-world treatment selection.
- GLP-1 medications are emerging as effective adjuncts for psoriasis patients struggling with weight and inflammation.
- Early intervention—especially with IL-23 blockers—may reduce flares, limit disease progression, and improve mental health outcomes.